Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 294

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Scleroderma lung disease

Open access
Solomon, Joshua J., Olson, Amy L., Fischer, Aryeh, Bull, Todd, Brown, Kevin K., Raghu, Ganesh·2013·European Respiratory Review
DOI 10.1183/09059180.00005512
Open this paper in CoChat — free account

Abstract

Systemic sclerosis (SSc) is a systemic autoimmune disease that is characterised by endothelial dysfunction resulting in a small-vessel vasculopathy, fibroblast dysfunction with resultant excessive collagen production and fibrosis, and immunological abnormalities. The classification of SSc is subdivided based on the extent of skin involvement into diffuse cutaneous sclerosis (dcSSc), limited cutaneous sclerosis (lcSSc) or SSc sine scleroderma [1]. While virtually any organ system may be involved in the disease process, fibrotic and vascular pulmonary manifestations of SSc, including interstitial lung disease (ILD) and pulmonary hypertension (PH), are the leading cause of death. As new therapies targeting these pulmonary conditions emerge, early recognition of lung involvement is essential for the care of these patients. In this article we review the direct and indirect pulmonary manifestations of SSc and recent therapeutic trials that have attempted to target these manifestations. When a patient with SSc disease presents with signs or symptoms referring to the chest, a number of potential disorders must be considered (table 1) for: direct pulmonary involvement (ILD with or without PH or pulmonary arterial hypertension (PAH), airways disease and pleural involvement); indirect pulmonary complications (aspiration, infection, drug toxicity, malignancy, respiratory muscle weakness, restrictive lung disease from chest wall involvement and lung disease secondary to cardiac involvement); combinations of direct and indirect pulmonary manifestations; and other lung diseases not related to SSc (chronic obstructive pulmonary disease/emphysema, asthma and lung nodules). View this table: Table 1. Pulmonary involvement in systemic sclerosis In scleroderma, the two most common types of direct pulmonary involvement are ILD and PH, which together account for 60% of SSc-related deaths [2]. While certain pulmonary manifestations may occur more commonly in a subset of SSc ( i.e. ILD is more common in dcSSc while PH is more common in lcSSc) [3], all of the known pulmonary manifestations reported have been described in each of …

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09059180.00005512

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Cited by

See all 294

Metadata

Authors
Solomon, J. J., Olson, A. L., Fischer, A., Bull, T., Brown, K. K., & Raghu, G.
Venue
European Respiratory Review
Publisher
European Respiratory Society (ERS)
Published
2013-02-28
Volume
22
Issue
127
Pages
6-19
ISSN
  • 0905-9180 (ISSN-L)
  • 1600-0617
DOI
10.1183/09059180.00005512
OpenAlex
W2098971028
Cited by
294
References
115
FWCI
10.23
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Scleroderma lung disease. https://app.cochat.ai/papers/10.1183/09059180.00005512
The paper
Solomon, J. J., Olson, A. L., Fischer, A., Bull, T., Brown, K. K., & Raghu, G. (2013). Scleroderma lung disease. European Respiratory Review. https://doi.org/10.1183/09059180.00005512

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.